BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:mazdutide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of mazdutide\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06884293-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:mazdutide: Phase 3 readout est. (NCT06884293)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study Comparing IBI362
  vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfu
 nction-associated Fatty Liver Disease （MAFLD）\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mazdutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06884293
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931028-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270507
DTEND;VALUE=DATE:20270508
SUMMARY:mazdutide: Phase 3 readout est. (NCT06931028)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2\nEstimated p
 rimary completion: 7 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/mazdutide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06931028
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:mazdutide: Phase 2 readout est. (NCT06143956)
DESCRIPTION:mazdutide\, phase 2\, Obesity.\nStudy: A Master Protocol Study 
 (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Pa
 rticipants With Obesity or Overweight\nEstimated primary completion: Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mazdutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614
 3956
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07135141-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:mazdutide: Phase na readout est. (NCT07135141)
DESCRIPTION:mazdutide\, phase na\, Obesity.\nStudy: Mazdutide as Adjuvant T
 herapy Following Sleeve Gastrectomy in Severe Obesity\nEstimated primary c
 ompletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/mazdutide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07135141
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255209-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:mazdutide: Phase 3 readout est. (NCT07255209)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Adolescents With Obesity or Overweight\nEstimated primary completion:
  31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maz
 dutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07255209
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07657676-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:mazdutide: Phase 4 readout est. (NCT07657676)
DESCRIPTION:mazdutide\, phase 4\, Obesity.\nStudy: Effect of Mazdutide on C
 oronary Plaque in Patients With Coronary Atherosclerosis and Overweight or
  Obesity\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/mazdutide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07657676
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824895-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:mazdutide: Phase 4 readout est. (NCT07824895)
DESCRIPTION:mazdutide\, phase 4\, Obesity.\nStudy: Mazdutide for Weight Man
 agement and Gout in Adults With Obesity\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mazdut
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07824895
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07713992-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:mazdutide: Phase na readout est. (NCT07713992)
DESCRIPTION:mazdutide\, phase na\, Type 2 Diabetes.\nStudy: Efficacy and Sa
 fety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate t
 o Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglut
 ide\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/mazdutide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07713992
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633639-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:mazdutide: Phase na readout est. (NCT07633639)
DESCRIPTION:mazdutide\, phase na\, Obesity.\nStudy: GLP-1 Therapy After Bar
 iatric Surgery in Chinese Patients With Obesity\nEstimated primary complet
 ion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mazd
 utide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07633639
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654062-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:mazdutide: Phase 4 readout est. (NCT07654062)
DESCRIPTION:mazdutide\, phase 4.\nStudy: Mazdutide for Adults With Prediabe
 tes: A Randomized\, Double-Blind\, Placebo-Controlled Trial (DREAM-PRE)\nE
 stimated primary completion: June 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/mazdutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07654062
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803705-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:mazdutide: Phase na readout est. (NCT07803705)
DESCRIPTION:mazdutide\, phase na\, Obesity.\nStudy: Efficacy of Mazdutide o
 n Fatty Pancreas\nEstimated primary completion: 30 June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/mazdutide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07803705
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767552-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:mazdutide: Phase na readout est. (NCT07767552)
DESCRIPTION:mazdutide\, phase na\, Type 2 Diabetes.\nStudy: Mazdutide for R
 emission of Type 2 Diabetes: Multicentre\, Double Blind\, Randomised\, Pla
 cebo Controlled Trial\nEstimated primary completion: 30 August 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/mazdutide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07767552
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517042-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:mazdutide: Phase na readout est. (NCT07517042)
DESCRIPTION:mazdutide\, phase na\, Obesity.\nStudy: ASCEND-1: Lifestyle Int
 ervention Plus Mazdutide for Weight Management\nEstimated primary completi
 on: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ma
 zdutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07517042
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897305-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:mazdutide: Phase na readout est. (NCT07897305)
DESCRIPTION:mazdutide\, phase na\, Obesity.\nStudy: Mazdutide for Reducing 
 Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients\n
 Estimated primary completion: 30 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/mazdutide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07897305
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718126-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:mazdutide: Phase 4 readout est. (NCT07718126)
DESCRIPTION:mazdutide\, phase 4\, Obesity.\nStudy: Pre-hepatectomy Rehabili
 tation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIM
 E)\nEstimated primary completion: 28 February 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/mazdutide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07718126
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775846-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:mazdutide: Phase 4 readout est. (NCT07775846)
DESCRIPTION:mazdutide\, phase 4.\nStudy: QUARTET-DKD: Quadruple Therapy for
  Type 2 Diabetic Nephropathy\nEstimated primary completion: 28 February 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/mazdutide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07775846
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07924553-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:mazdutide: Phase na readout est. (NCT07924553)
DESCRIPTION:mazdutide\, phase na.\nStudy: Efficacy\, Safety and Cardiovascu
 lar Protection of Mazdutide in Type 1 Diabetes\nEstimated primary completi
 on: 1 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maz
 dutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07924553
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797101-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:mazdutide: Phase na readout est. (NCT07797101)
DESCRIPTION:mazdutide\, phase na.\nStudy: Body-weight Reduction Effect on P
 ortal Hypertension in Compensated Cirrhosis\nEstimated primary completion:
  31 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mazduti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7797101
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07781150-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:mazdutide: Phase 2 readout est. (NCT07781150)
DESCRIPTION:mazdutide\, phase 2\, Obesity.\nStudy: Mazdutide Plus LNG-IUS f
 or Fertility-Sparing Treatment of AEH or Early Endometrial Cancer\nEstimat
 ed primary completion: 30 June 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/mazdutide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07781150
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07083154-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:mazdutide: Phase 3 readout est. (NCT07083154)
DESCRIPTION:mazdutide\, phase 3\, Type 2 Diabetes.\nStudy: Mazdutide in Typ
 e 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)\nEsti
 mated primary completion: 1 August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/mazdutide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07083154
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
